The center will specialize in collecting concentrated white blood cell biospecimens through apheresis (a.k.a. leukopaks) from participants in Sanguine's Patient Community network.

We strongly believe that the right leaders, setting standards early in this new field, will create an essential environment of patient safety and trust,” said Amy DuRoss, CEO at Vineti.